ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0202

Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features

Elena Joerns1, Traci Adams1, Chad Newton1, Lesley Davila2, Kiran Batra1, Jose Torrealba1, Craig Glazer1, Joan Reisch1, Bonnie Bermas3, David Karp2 and Una Makris4, 1UT Southwestern, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UTSouthwestern Medical Center, Dallas, TX, 4UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Cohort Study, interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus, we currently have no data to guide optimal IPAF patient selection for therapy or the optimal immunosuppressive regimen in IPAF. In this study, we use a rigorously phenotyped cohort (based on published IPAF criteria) to characterize features associated with response to immunosuppressive treatment.

Methods: We conducted a retrospective cohort study of 65 IPAF patients to evaluate for serologic, clinical, and radiographic characteristics associated with response to immunosuppression, defined as % relative functional vital capacity (FVC) decline of less than 10%, and absence of death or lung transplant within the first year of continuous immunosuppressive therapy. We used Fisher’s exact test, chi-squared test, and Mann Whitney U test, as appropriate, to evaluate for significant differences in characteristics between patients with significant progression and those who did not progress. Multivariate logistic regression was used to further evaluate significant variables while controlling for confounders.

Results: No baseline features predicted IPAF progression while on treatment, There was a trend of greater progression amongst men, ever smokers, and those with UIP radiographic pattern, although the differences were not statistically significant (Table 1). There was a statistically significant difference in the proportion of patients who were treated with combination therapy of mycophenolate mofetil (MMF) and prednisone whose disease did not progress.

Conclusion: Our study suggests that a combination therapy with MMF and prednisone may be associated with lack of progression in IPAF, including IPAF-UIP, although causality cannot be established. In the future studies, knowledge of cytokine profiles in different IPAF phenotypes may inform management in the early stages of the disease.

Table 1: Baseline characteristics of the IPAF cohort


Disclosures: E. Joerns, Pfizer, Inc, 5; T. Adams, None; C. Newton, Boehringer-Ingelheim, 2; L. Davila, None; K. Batra, None; J. Torrealba, None; C. Glazer, None; J. Reisch, None; B. Bermas, None; D. Karp, None; U. Makris, None.

To cite this abstract in AMA style:

Joerns E, Adams T, Newton C, Davila L, Batra K, Torrealba J, Glazer C, Reisch J, Bermas B, Karp D, Makris U. Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/variables-associated-with-response-to-therapy-in-patients-with-interstitial-pneumonia-with-autoimmune-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/variables-associated-with-response-to-therapy-in-patients-with-interstitial-pneumonia-with-autoimmune-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology